November 3, 2017 / 12:57 PM / 8 months ago

BRIEF-Sarepta Therapeutics says FDA clears gene therapy IND application

Nov 3 (Reuters) - Sarepta Therapeutics Inc-

* Sarepta Therapeutics and Nationwide Children’S Hospital announce U.S. Food And Drug Administration (FDA) clearance of the IND application for the GALGT2 gene therapy program

* Sarepta Therapeutics- ‍IND application for GALGT2 gene therapy program was cleared by FDA​

* Sarepta Therapeutics - Nationwide Children's is on track to initiate Phase 1/2A clinical trial in individuals with DMD by year-end 2017 ​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below